Patents by Inventor Chrisantha H. Senanayake
Chrisantha H. Senanayake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150299102Abstract: Methods of preparing, and compositions comprising, derivatives of (?)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.Type: ApplicationFiled: July 1, 2015Publication date: October 22, 2015Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Nandkumar N. Bhongle
-
Patent number: 9072700Abstract: Methods of preparing, and compositions comprising, derivatives of (?)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.Type: GrantFiled: December 23, 2013Date of Patent: July 7, 2015Assignee: Sunovion Pharmaceuticals Inc.Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Nandkumar N. Bhongle
-
Publication number: 20140121283Abstract: Methods of preparing, and compositions comprising, derivatives of (?)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.Type: ApplicationFiled: December 23, 2013Publication date: May 1, 2014Applicant: Sunovion Pharmaceuticals Inc.Inventors: Thomas P. JERUSSI, Chrisantha H. SENANAYAKE, Nandkumar N. BHONGLE
-
Patent number: 8642662Abstract: Methods of preparing, and compositions comprising, derivatives of (?)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.Type: GrantFiled: May 25, 2012Date of Patent: February 4, 2014Assignee: Sunovion Pharmaceuticals Inc.Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Nandkumar N. Bhongle
-
Publication number: 20120302794Abstract: Methods of preparing, and compositions comprising, derivatives of venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.Type: ApplicationFiled: August 9, 2012Publication date: November 29, 2012Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Nandkumar N. Bhongle
-
Patent number: 8269040Abstract: Methods of preparing, and compositions comprising, derivatives of venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.Type: GrantFiled: November 25, 2003Date of Patent: September 18, 2012Assignee: Wyeth LLCInventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Nandkumar N. Bhongle
-
Publication number: 20120232157Abstract: Methods of preparing, and compositions comprising, derivatives of (?)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.Type: ApplicationFiled: May 25, 2012Publication date: September 13, 2012Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Nandkumar N. Bhongle
-
Publication number: 20080132578Abstract: Methods of preparing, and compositions comprising, derivatives of venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.Type: ApplicationFiled: January 23, 2008Publication date: June 5, 2008Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Nandkumar N. Bhongle
-
Patent number: 7071234Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3 antagonists.Type: GrantFiled: March 25, 2003Date of Patent: July 4, 2006Assignee: Sepracor Inc.Inventors: Thomas P Jerussi, Chrisantha H. Senanayake, Qun K. Fang
-
Patent number: 7034059Abstract: The invention encompasses methods of using racemic and enantiomerically pure norfluoxetine, as well as pharmaceutical compositions, pharmaceutical unit dosage forms, and kits comprising racemic and enantiomerically pure norfluoxetine. In particular, the invention encompasses a method of inhibiting or reducing the production of PGE2. The invention further encompasses a method of treating or preventing inflammation in a patient, as well as a method of treating or preventing a disease or disorder such as, but not limited to, autoimmune diseases, arthritis, neurologic diseases, inflammatory diseases, fibromyalgia, pain resulting from inflammation, neuropathic pain, and cancer.Type: GrantFiled: June 28, 2002Date of Patent: April 25, 2006Assignee: Sepracor Inc.Inventors: Mark G. Currie, Steven W. Jones, Chrisantha H. Senanayake, Zhi-Hiu Lu
-
Patent number: 6974837Abstract: Pharmaceutical compositions and dosage forms are disclosed that comprise a racemic or optically pure sibutramine metabolite and a phosphodiesterase inhibitor.Type: GrantFiled: October 23, 2002Date of Patent: December 13, 2005Assignee: Sepracor Inc.Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Qun K. Fang
-
Patent number: 6946464Abstract: The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (?)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (?)-N-desmethylzopiclone.Type: GrantFiled: January 13, 2003Date of Patent: September 20, 2005Assignee: Sepracor Inc.Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Paul D. Rubin, Yaping Hong, Roger A. Bakale, Tingjian Xiang, Fran A. McConville
-
Patent number: 6911479Abstract: Methods of preparing, and compositions comprising, derivatives of (?)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.Type: GrantFiled: August 19, 2002Date of Patent: June 28, 2005Assignee: Sepracor Inc.Inventors: Thomas P Jerussi, Chrisantha H Senanayake, Nandkumar N. Bhongle
-
Publication number: 20040180952Abstract: Methods of preparing, and compositions comprising, derivatives of (−)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.Type: ApplicationFiled: March 23, 2004Publication date: September 16, 2004Applicant: Sepracor Inc.Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Nandkumar N. Bhongle
-
Publication number: 20040106576Abstract: Methods of preparing, and compositions comprising, derivatives of venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.Type: ApplicationFiled: November 25, 2003Publication date: June 3, 2004Applicant: Sepracor Inc.Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Nandkumar N. Bhongle
-
Publication number: 20040067957Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence.Type: ApplicationFiled: September 22, 2003Publication date: April 8, 2004Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Qun K. Fang
-
Publication number: 20030195261Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutrarnine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3 antagonists.Type: ApplicationFiled: March 25, 2003Publication date: October 16, 2003Applicant: Sepracor Inc.Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Qun K. Fang
-
Publication number: 20030166657Abstract: The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone.Type: ApplicationFiled: January 13, 2003Publication date: September 4, 2003Applicant: Sepracor, Inc.Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Paul D. Rubin, Yaping Hong, Roger A. Bakale, Tingjian Xiang, Fran A. McConville
-
Publication number: 20030119841Abstract: The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone.Type: ApplicationFiled: September 30, 2002Publication date: June 26, 2003Applicant: Sepracor, Inc.Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Paul D. Rubin, Yaping Hong, Roger A. Bakale, Tingjian Xiang, Fran A. McConville
-
Publication number: 20030096792Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence.Type: ApplicationFiled: October 23, 2002Publication date: May 22, 2003Applicant: Sepracor, Inc.Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Qun K. Fang